Uemura · Amino acids 2026 · narrative review · n=?

Polyamine metabolism as a regulator of cellular and organismal aging.

Cited 4 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing mechanistic, preclinical, and limited clinical literature without systematic methodology.

PubMed 41617890 · doi:10.1007/s00726-026-03497-2 · record verified 2026-08-30

What was done

The authors synthesized literature on polyamine metabolism (putrescine, spermidine, and spermine) and its role in cellular homeostasis, senescence, and organismal longevity. They reviewed mechanisms including polyamine biosynthesis and transport, spermine oxidase (SMOX) catabolism, epigenetic modifications, eIF5A hypusination, and translation control, contrasting preclinical findings with current human clinical evidence.

What was found

The abstract reports no quantitative data or specific effect sizes. Preclinically, intracellular polyamine levels decline with age, and spermidine supplementation extends lifespan and enhances cognitive and cardiac performance in model organisms. Age-associated upregulation of SMOX generates toxic acrolein, inducing oxidative stress and cellular senescence, whereas inhibiting SMOX reduces DNA damage and senescence markers. Polyamine metabolism also modulates DNA methylation, histone acetylation, and eIF5A-dependent translation. Human clinical data remain sparse, showing inconsistent results attributed to differences in bioavailability and metabolic conversion.

Why it matters

This review highlights polyamine homeostasis—particularly catabolic enzyme modulation and dietary or probiotic supplementation—as an integrated hub linking redox balance, translation, and epigenetics in aging research. It identifies spermine catabolism (specifically SMOX inhibition) as a distinct therapeutic target alongside polyamine replacement strategies.

Limits

The abstract provides no quantitative metrics, meta-analytic data, or systematic search parameters. Most mechanistic insights and lifespan extensions are derived from non-human model organisms, and human translation is currently hindered by limited trial data, variable clinical outcomes, and unoptimized bioavailability.

Cited by